Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From cbdstockwatcher on the MGCLF board.
- MGC Pharmaceuticals (MXC) has appointed Nicole Godresse as Global Chief Sales Officer, effective immediately
- Nicole has more than 20 years experience in the pharmaceutical and healthcare industries, having worked with the likes of Johnson & Johnson and Eli Lilly
- Her most recent role at Tilray saw her play a part in launching the first medical cannabis brand legally in Australia and New Zealand
- She also helped launch one of the first medical cannabis clinics in the country and deliver some of Australia's first government-funded medical cannabis trials
https://themarketherald.com.au/mgc-pharmaceuticals-asxmxc-appoints-nicole-godresse-as-global-chief-sales-officer-2021-01-13/
Nicole's target (KPI) is for MGC Pharmaceuticals to reach $1million in sales per month.
https://www.proactiveinvestors.com.au/companies/news/939936/mgc-pharma-s-new-head-of-global-sales-has-big-ambitions-and-says-they-re--ready-to-go--939936.html
They do that all the time, report something, only to drop it as the night progresses. This time they are not even showing volume ?
OGI opened on 1/4/21 @ $1.36 closed today $2.41
Looks like the Cannabis sector is on the move.
https://www.booker.senate.gov/news/press/booker-wyden-schumer-joint-statement-on-cannabis-reform-legislation
Thats right, a JOINT statement. lol.
https://www.booker.senate.gov/news/press/booker-appointed-to-senate-agriculture-committee
ALEAF was 0.51 on 2/1/21. Closed today 0.698
SOLCF was up .24 today, based on one of its holdings VERANO Holdings doing an IPO next week. Should be good for another .50 hopefully.
No. The ticker for the IPO has not yet been announced. I tagged $SOL because they own 12.6% of Verano and it is a way of indirectly investing in Verano ahead of the IPO for those who feel inclined to do so 😊 pic.twitter.com/9jVrswtCeO
— jungle.java (@junglejava1) January 22, 2021
Took a minute position in AMYZF - small cash balance in an account.
Giddy up
Looks like the GME action may be trailing off today.
Meanwhile CYDY is up $1.00+ and is trading over 9.2MM.
BANG !
The BANG stocks (Blackberry (NYSE: BB), AMC Entertainment (NYSE: AMC), Nokia Inc. (NYSE: NOK), GameStop Corp (NYSE: GME) are experiencing wild price swings in recent days. GameStop is on a meteoric run up in price fueled by what CNBC called a “Reddit Rebellion.”
https://insiderfinancial.com/reddit-rebellion-targeting-the-short-mafia-next/180939/
What interesting times.
I see over on Reddit, they are saying they are not the cause of any perceived silver short, it is just naturally organic.
Am waiting to see how they will proceed against Zuckerberg and his need to feed off of peoples data.
I think it will come to pass tomorrow, Monday. A few minutes ago I was seeing B/A $29/$30, now it's down to $28/$29. Spread has gone from $0.10 to $1.00 in my neck of the woods. I also just looked up Reddit users, and Google says 330 million monthly active users, of which USA is under 25 million.
https://www.kitco.com/news/video/show/Market-Analysis/3193/2021-01-31/Silver-price-moves-6-on-short-squeeze-pressure-is-that-it-Phil-Streible#_48_INSTANCE_puYLh9Vd66QY_=https%3A%2F%2Fwww.kitco.com%2Fnews%2Fvideo%2Flatest%3Fshow%3DMarket-Analysis
The times are about to get more interesting.
https://www.reddit.com/r/Silverbugs/comments/l6fnto/rwallstreetbets_looks_like_it_might_start_leaning/
WSJ interviewed a guy about GME, he said -
“Please tell the wolf of
Wall Street that the pigeon of
San Francisco is gonna eat your
lunch,”
Seen on another board....
Reported on another board that the Schall Attorney's office had to take their call center offline due to being flooded with angry phone calls. LOL. I guess they didn't know they were messing with Cytonuts!
Ain't that something. A message board recommends buying a stock, and hedge funds are annoyed by that.
I would have thought that funds were selling to get cash to cover their underwater shorts, however volume does not support that. Will have to wait for tomorrow to see.
Had to share this Mathematics:
This comes from 2 math teachers with a combined total of 70 yrs. experience.
It has an indisputable mathematical logic.
This is a strictly ..... mathematical viewpoint.... and it goes like this:
What Makes 100%?
What does it mean to give MORE than 100%?
Ever wonder about those people who say they are giving more than 100%? We have all been to those meetings where someone wants you to give over 100%.
How about achieving 103%?
What makes up 100% in life?
Here's a little mathematical formula that might help you answer these questions:
If:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Is represented as:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26..
Then:
H-A-R-D-W-O-R-K
8+1+18+4+23+15+18+11 = 98%
And
K-N-O-W-L-E-D-G-E
11+14+15+23+12+5+4+7+5 = 96%
But ,
A-T-T-I-T-U-D-E
1+20+20+9+20+21+4+5 = 100%
And,
B-U-L-L-S-H-I-T
2+21+12+12+19+8+9+20 = 103%
AND, look how far ass kissing will take you.
A-S-S-K-I-S-S-I-N-G
1+19+19+11+9+19+19+9+14+7 = 118%
So, one can conclude with mathematical certainty, that while Hard work and Knowledge will get you close, and Attitude will get you there.
Its the Bullshit and Ass Kissing that will put you over the top.
Now you know why some people are where they are!
Australian daily volume can be seen on Yahoo Finance, under MXC.AX
https://finance.yahoo.com/quote/MXC.AX/history?p=MXC.AX
During the quarter, MGC Pharma completed the 100% acquisition of the operating telehealth clinic-based assets, data and intellectual property of Medicinal Cannabis Clinics (MCC), a wholly owned subsidiary of Cannvalate Pty Ltd, with over 300 patient consults conducted since completion on the 23rd of November. This following the signing of a binding term sheet in July 2020. Consideration of $1m MGC Pharma Ordinary Shares (2/3 subject to trading restrictions) and $400,000 in cash has been paid for the acquisition.
Alongside revenue generated from consults, this acquisition provides MGC Pharma with an operating platform with both import and export capacity that will significantly expand market access and provide control of the supply chain from manufacturing through to patients.
The acquisition also allows the Company to continue providing its high-quality GMP certified medications to patients in Australia and further improves profit margins while keeping product at the current competitive prices.
The acquisition of the MCC Assets is the next step in building on-the-ground distribution assets allowing the Company to wholesale and distribute directly to other clinics and pharmacies to reduce storage and distribution costs.
Launch of CannEpil® App
As part of its ongoing work with the Royal Melbourne Institute of Technology (RMIT), MGC Pharma launched the CannEpil® App, and is providing medical access to the International Library of Cannabinoids (ILC).
The App is a cross platform application available to download from both the Apple App Store and Google Play Store and is designed to be used by patients (or the patient’s guardian) taking CannEpil® as a prescription treatment. The App will record patient responses to medical questionnaires as part of their treatment plan and the treating practitioner will be able to view the responses in real-time.
The ILC is a world first centralised platform compiling the diverse range of existing data on the therapeutic benefits of cannabinoids. The ILC database has been designed to collect comprehensive information about clinical trials, including details of diseases and follow up treatments, as well as product identifiers, including genetics, grow conditions and chemical profile to provide doctors with an encyclopaedia of exhaustive information on the best treatment for patients using cannabinoids.
First shipment of MP Line products directly to patients in Brazil
MGC Pharma’s first batch of MP Line products were shipped directly to patients in Brazil in October 2020, through its binding supply and distribution agreement with Brazil-based ONIX Empreendimentos e Participações (‘ONIX’). MGC Pharma is the first company globally to ship high THC formulations directly to a patient’s door in Brazil, without the need to visit a pharmacy.
The shipment was completed under Brazil’s Compassionate Use Program following the receipt of patients’ prescriptions provided by an ONIX referring doctor. ONIX currently has more than 100 referring doctors in Brazil able to prescribe cannabinoid products under the Compassionate Use Program and is targeting to have over 1,000 referring doctors by mid-2021.
Research and Development
Completion of Phase II clinical trial on COVID-19 patients
MGC Pharma’s Phase II double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of anti-inflammatory treatment, ArtemiCTM, on 50 patients diagnosed with COVID-19 has completed.
The trial included 50 patients of which 33 were in the treatment group and 17 in the placebo group and took place across three independent hospital sites across Israel and India.
The full results have demonstrated to improve the health status of COVID-19 patients delivering a NEWS score of less than or equal to 2. None of the patients in the treatment group required additional oxygen, mechanical ventilation or admission to intensive care where all of these events were reported in the placebo group. The average NEWS score of patients in the placebo group was 2.25 statistically significantly higher (p<0.04) than in the treatment group – 0/5.
The Trial met all the FDA requirements for a COVID-19 study including population diversity (age, medical history, and genetic diversity) and demonstrated a full safety profile with no drug related adverse events. This resulted due to ArtemiCTM and the trial being focused on the immunomodulation specific for the prevention of cytokines storm, as opposed to other immunomodulators.
These results also follow safety and toxicity testing completed on mice and in line with FDA requirements for product registration requiring two types of rodents in pre-clinical trials. MGC Pharma completed an in vivo safety and toxicity pre-clinical study, including histology testing, on 24 rats. This included four groups with three study drug dosages being 48ug, 96ug and 196ug per kg rat and a control group.
The rats were observed and tested for clinical changes over seven days. This study included pathological examination of the organs: liver, heart, brain, spleen, spinal cord, sciatic nerve, kidney (L+R), lungs and tongue.
Further successful results from pre-clinical glioblastoma research
Results from the ongoing pre-clinical research program focused on evaluating cannabinoid formulations in the development of a treatment of the most aggressive and therapeutically resistant brain tumour, glioblastoma, have shown further successful results.
The pre-clinical in-vitro research program is being conducted in collaboration with the National Institute of Biology (‘NIB’) and the Neurosurgery Department at the University Medical Centre in Ljubljana, Slovenia.
The results from 18 patient tumour samples show for the first time that the Company’s proprietary formulation, CBG, exerts a superior effect in impairing the major hallmarks of glioblastoma progression, i.e. fast proliferation and invasion, and particularly enhancing glioblastoma cell death. Moreover, CBG can destroy therapy-resistant glioblastoma stem cells, which are the root of cancer development and extremely resistant to various treatments of this lethal cancer. CBG should present a new yet unexplored modality of glioblastoma therapy that could replace Tetrahydrocannabinol (THC) as a more acceptable add-on or adjuvant treatment strategy.
Financial and Corporate
Completion of unmarketable share parcel
The Company completed the sale of 50,696,634 fully paid ordinary shares pursuant to the Company’s Unmarketable Parcel Sale Facility (UMP Facility). MGC Pharma confirms its shareholder base has now been reduced by 5,067 shareholders. This will significantly reduce the Company’s administrative and corporate costs moving forward.
Progress towards completion of MGC Nutraceuticals sale to Onassis
As announced on 2nd December 2020, under the terms of the sale and purchase agreement for the 100% sale of the Company’s subsidiary MGC Nutraceuticals, MGC Pharma will receive shares equating to a value of US$6 million in Onassis Holdings Corp and the Company has secured an exclusive supply agreement for the provision of its CBD, raw materials and proprietary production intellectual property (IP). This follows the signing of a binding acquisition and exclusive CBD supply agreement as announced on 18 June 2020.
During the quarter MGC Pharma provided the 30 June 2020 audited financial statements for MGC Nutraceuticals to Onassis and full settlement of the acquisition is expected to complete over the next quarter. During the December quarter Onassis has commenced the process of finalising the offering submissions for the capital raising with the US SEC. The process from submission to completion is currently expected to complete in H1 2021. Once the offering submission has been approved, Onassis will complete the capital raising which will enable the full and complete settlement of the MGC Nutraceuticals acquisition with MGC Pharma.
Long terms benefits from UN vote to reschedule cannabis
In early December 2020, the United Nations (UN) voted in favour of the removal of cannabis and its derivatives from schedule IV in recommendations from the World Health Organisation (WHO). Cannabis and its derivativities are now contained under Schedule I of the 1961 UN Single Convention on Narcotic Drugs.
This creates a significant opportunity for MGC Pharma by removing red-tape that creates logistical limitations of the movement of products and creates an open pathway for easier and cheaper global distribution. This will also enable significantly more commercial opportunities for MGC Pharma by allowing it to deliver its Mercury Pharma product line to new markets going forward.
Appendix 4C
The Company had $1.57m cash at the end of the December 2020 quarter, with access to $9.25m undrawn from its $15m financing facility with Mercer Street Opportunity Fund LLC (as announced to the ASX on 10 September 2020). In accordance with Section 6 of the attached Appendix 4C, the Company confirms the total $480k was for executive director fees, non-executive director fees and corporate costs during the quarter.
As detailed in the Appendix 4C, expenditure for the quarter has been spent on $1.484m for research and development, $1.363m for manufacturing and operating costs, $152k for advertising and marketing, $258k staffing costs and $852k for administration and corporate costs.
https://stocknessmonster.com/announcements/mxc.asx-6A1016539/
Gives a link to a December quarterly report.
Seems like they are doing a Lazarus comeback.
With Shares Outstanding of 1,788,130,339 then 10MM could be a forgotten account. If the volume picks up over the next 2 weeks, we'll know for sure - something's up. Even today is about 1/2 MM over average. They do seem opportune for a 1 :100 Reverse split.
When I was young, I decided to go to medical school. At the entrance exam, we were asked to rearrange the letters
P N E I S
and form the name of an important body part which is most useful when erect.
Those who answered SPINE are doctors today, while the rest are on tik tok.
MGCLF
Wonder what's going on today, trading went from average 119k to 10.1M.
MGC Pharma attracts $5m grant for its Malta-based production facility.
https://stockhead.com.au/health/mgc-pharma-attracts-5m-grant-for-its-malta-based-production-facility/
MGC Pharmaceuticals confirms Phase II trial success for anti-inflammatory COVID treatment
https://stockhead.com.au/health/mgc-pharmaceuticals-confirms-phase-ii-trial-success-for-anti-inflammatory-covid-treatment/
Nancy Pelosi’s Husband Bought Stock Options in Apple, Tesla, and Disney.
https://www.barrons.com/articles/nancy-pelosi-husband-bought-apple-tesla-disney-stock-options-51611496598
https://seekingalpha.com/article/4400645-microsoft-apple?utm_medium=email&utm_source=seeking_alpha#alt1&mail_subject=msft-microsoft-or-apple-the-showdown&utm_campaign=rta-stock-article&utm_content=link-2
There is an added element that should be weighed when considering Mac/iPad revenues. The development of the M1 chip, which will be used in the Macintosh line of computers, is estimated to cost $40 to $50 per unit versus $200 spent on the Core i5 processor it replaced. If those figures are correct, Apple would harvest $2.5 billion in savings over the next fiscal year. There are reasons to believe the actual costs for the transition to the M1 from the i5 will be double the quoted figure. Nonetheless, the savings would still be substantial.
https://clinicaltrials.gov/ct2/show/NCT04382040?term=ArtemiC&draw=2&rank=1
Wow, Frankincense.
ArtemiC is a medical spray comprised of Artemisinin (6 mg/ml), Curcumin (20 mg/ml), Frankincense (=Boswellia) (15 mg/ml) and vitamin C (60 mg/ml) in micellar formulation for spray administration.
Fantastic, I was so focused on Laredo, I forgot about SORC. So basically the group is Laredo Oil, Stranded Oil, Natrona, Caddo and Cat Creek (50% interest).
Natrona County Holdings LLC, here are some related links,
https://www.dnb.com/business-directory/company-profiles.natrona_county_holdings_llc.7427878e4876c568f640804b1b2069cd.html
http://www.drillingedge.com/wyoming/operators/natrona-county-holdings-llc/2510
https://www.shaleexperts.com/company/Natrona-County-Holdings-LLC#
https://www.shalexp.com/natrona-county-holdings-llc
https://www.manta.com/c/mh0h352/natrona-county-holdings-llc
Caddo Parish Holdings LLC, here are some related links -
http://www.drillingedge.com/louisiana/operators/caddo-parish-holdings-llc/c426
http://www.drillingedge.com/louisiana/operators/caddo-parish-holdings-llc/c426
https://www.manta.com/c/mh0h352/natrona-county-holdings-llc
https://thedrillings.com/owners/2357306
What we need now is to consistently be trading over 500,000 per day. Price follows volume.
Why I'm invested in Laredo Oil. My comments are in italics, and the text is from the last 10Q.
As consideration for the SORC Shares, Buyer paid to Alleghany $55,000 and the Company agreed to pay to Alleghany a revenue royalty of 5.0% of the Company’s future revenues and net profits relating to oil, gas, gas liquids and all other hydrocarbons, subject to certain adjustments, for a period of seven years after the closing.
So with the ability to freely utilize UGD 3.0 technology, they have to pay a minute royalty of 5%.
Further, pursuant to the SORC Purchase Agreement, Laredo and Alleghany entered into a Consulting Agreement dated as of December 31, 2020 (the “Consulting Agreement”), pursuant to which Seller agreed to pay an aggregate of approximately $1.245 million during calendar year 2021 in consideration of Laredo causing certain individuals, including Mark See, Laredo’s Chief Executive Officer and Chairman, and Chris Lindsey, Laredo’s General Counsel and Secretary, to provide consulting services to Alleghany (for a period of three years for Mr. See and one year for Mr. Lindsey).
They will still have consulting revenue from Alleghany.
In connection with the SORC Purchase Transaction, the notes were amended, restated and consolidated into one note including all accrued interest through December 31, 2020, the date of the transaction, for a total of $631,434 (the “Senior Consolidated Note”) with a maturity date of June 30, 2022. The Senior Consolidated Note requires any stock issuances for cash be utilized to pay down the outstanding loan balance unless written consent is obtained from Alleghany. As part of the SORC Purchase Transaction, the Company agreed to secure repayment of the Senior Consolidated Note with certain equipment owned by SORC Holding and to reduce the note balance with any proceeds received from any sales of such equipment. The note bears no interest until January 1, 2022 whereupon the interest rate increases to 5% per annum through maturity. Principal with all accrued and unpaid interest is due at maturity.
A 1 year interest free loan, and then 5% for 6 months next year when it becomes due on June 30.
The Company plans to use its cash and cash equivalents on hand, and the proceeds from the Consulting Agreement, to maintain the mineral rights acquisition program in Montana and to pay its operating costs.
Planning future expansion.
No warrants were issued during the first two quarters of fiscal years 2021 or 2020. As of November 30, 2020, there were 5,374,501 warrants remaining to be exercised at a price of $0.70 per share to Sunrise Securities Corporation to satisfy the finders’ fee obligation associated with the Alleghany transaction. The warrants will expire June 14, 2021 and are currently exercisable.
http://www.sunrisecorp.com/#:~:text=Sunrise%20Securities*%20("Sunrise",80%20domestic%20and%20international%20companies.
So instead of paying the fees associated with the Alleghany deal, they issued warrants to an Investment bank, which will expire in 5 months. So on June 14, 2021 if the Bank wants in on the action, they have to pony up $3,762,150.70
The Outstanding number of shares is 54,514,765, and has been that amount for the past 3 years. The float is 19,493,232.
But what is even more impressive to me, as a former banker,
The balance sheet is DEVOID OF GOODWILL.
The balance sheet is DEVOID OF INTANGIBLES.
Got another 100k LRDC today @ $0.064. Will post what I like about the stock in a couple of days, spent the whole long weekend digging into them.
Wish SELB would revisit its glory days.
Reminds me of AMRN, which was setback by a single question at their ADCOM meeting. Will be carrying those wounds for many years to come, unless LL provides a $$ transfusion.